Efficacy of Tumor Necrosis Factor Antagonist Treatment in Patients With Refractory Ulcerative Proctitis.
Fiche publication
Date publication
juin 2019
Journal
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Pineton de Chambrun G, Amiot A, Bouguen G, Viennot S, Altwegg R, Louis E, Collins M, Fumery M, Poullenot F, Armengol L, Buisson A, Abitbol V, Laharie D, Seksik P, Nancey S, Blanc P, Bouhnik Y, Pariente B, Peyrin-Biroulet L,
Lien Pubmed
Résumé
It is a challenge to manage patients with ulcerative proctitis, UP) refractory to standard therapy. We investigated the effectiveness of tumor necrosis factor, TNF) antagonists in a large cohort of patients with refractory UP.
Mots clés
immune suppression, inflammatory bowel disease, proctitis, second-line treatment, trial
Référence
Clin. Gastroenterol. Hepatol.. 2019 Jun 13;: